BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24736581)

  • 1. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
    Lankheet NA; Kloth JS; Gadellaa-van Hooijdonk CG; Cirkel GA; Mathijssen RH; Lolkema MP; Schellens JH; Voest EE; Sleijfer S; de Jonge MJ; Haanen JB; Beijnen JH; Huitema AD; Steeghs N
    Br J Cancer; 2014 May; 110(10):2441-9. PubMed ID: 24736581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
    Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
    Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
    J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
    Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
    DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
    Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
    Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
    Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
    Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
    Rudek MA; Moore PC; Mitsuyasu RT; Dezube BJ; Aboulafia D; Gerecitano J; Sullivan R; Cianfrocca ME; Henry DH; Ratner L; Haigentz M; Dowlati A; Little RF; Ivy SP; Deeken JF
    Cancer; 2014 Apr; 120(8):1194-202. PubMed ID: 24474568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
    J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
    Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
    Rovithi M; Gerritse SL; Honeywell RJ; Ten Tije AJ; Ruijter R; Peters GJ; Voortman J; Labots M; Verheul HMW
    J Clin Oncol; 2019 Feb; 37(5):411-418. PubMed ID: 30586316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
    Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
    Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
    Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
    Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
    Hamberg P; Steeghs N; Loos WJ; van de Biessen D; den Hollander M; Tascilar M; Verweij J; Gelderblom H; Sleijfer S
    Br J Cancer; 2010 Jun; 102(12):1699-706. PubMed ID: 20485286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
    Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.